178 related articles for article (PubMed ID: 17592122)
1. Self-vaccination by methamphetamine glycation products chemically links chronic drug abuse and cardiovascular disease.
Treweek J; Wee S; Koob GF; Dickerson TJ; Janda KD
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11580-4. PubMed ID: 17592122
[TBL] [Abstract][Full Text] [Related]
2. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.
Lee NR; Zheng G; Leggas M; Janganati V; Nickell JR; Crooks PA; Bardo MT; Dwoskin LP
J Pharmacol Exp Ther; 2019 Nov; 371(2):526-543. PubMed ID: 31413138
[TBL] [Abstract][Full Text] [Related]
3. Drugs of abuse that mediate advanced glycation end product formation: a chemical link to disease pathology.
Treweek JB; Dickerson TJ; Janda KD
Acc Chem Res; 2009 May; 42(5):659-69. PubMed ID: 19275211
[TBL] [Abstract][Full Text] [Related]
4. Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion.
Schwendt M; Rocha A; See RE; Pacchioni AM; McGinty JF; Kalivas PW
J Pharmacol Exp Ther; 2009 Nov; 331(2):555-62. PubMed ID: 19648469
[TBL] [Abstract][Full Text] [Related]
5. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
McFadden LM; Hadlock GC; Allen SC; Vieira-Brock PL; Stout KA; Ellis JD; Hoonakker AJ; Andrenyak DM; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2012 Feb; 340(2):295-303. PubMed ID: 22034657
[TBL] [Abstract][Full Text] [Related]
6. Chronic wheel running-induced reduction of extinction and reinstatement of methamphetamine seeking in methamphetamine dependent rats is associated with reduced number of periaqueductal gray dopamine neurons.
Sobieraj JC; Kim A; Fannon MJ; Mandyam CD
Brain Struct Funct; 2016 Jan; 221(1):261-76. PubMed ID: 25273280
[TBL] [Abstract][Full Text] [Related]
7. Immunological consequences of methamphetamine protein glycation.
Dickerson TJ; Yamamoto N; Ruiz DI; Janda KD
J Am Chem Soc; 2004 Sep; 126(37):11446-7. PubMed ID: 15366884
[TBL] [Abstract][Full Text] [Related]
8. Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.
McFadden LM; Vieira-Brock PL; Hanson GR; Fleckenstein AE
Neuropharmacology; 2015 Jun; 93():146-54. PubMed ID: 25645392
[TBL] [Abstract][Full Text] [Related]
9. Methamphetamine decreases CD4 T cell frequency and alters pro-inflammatory cytokine production in a model of drug abuse.
Mata MM; Napier TC; Graves SM; Mahmood F; Raeisi S; Baum LL
Eur J Pharmacol; 2015 Apr; 752():26-33. PubMed ID: 25678251
[TBL] [Abstract][Full Text] [Related]
10. Neurochemical and behavioral comparisons of contingent and non-contingent methamphetamine exposure following binge or yoked long-access self-administration paradigms.
Schweppe CA; Burzynski C; Jayanthi S; Ladenheim B; Cadet JL; Gardner EL; Xi ZX; van Praag H; Newman AH; Keck TM
Psychopharmacology (Berl); 2020 Jul; 237(7):1989-2005. PubMed ID: 32388619
[TBL] [Abstract][Full Text] [Related]
11. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of D₂-mediated dopamine transmission in monkeys after chronic escalating methamphetamine exposure.
Groman SM; Lee B; Seu E; James AS; Feiler K; Mandelkern MA; London ED; Jentsch JD
J Neurosci; 2012 Apr; 32(17):5843-52. PubMed ID: 22539846
[TBL] [Abstract][Full Text] [Related]
13. Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats.
Tunstall BJ; Ho CP; Cao J; Vendruscolo JCM; Schmeichel BE; Slack RD; Tanda G; Gadiano AJ; Rais R; Slusher BS; Koob GF; Newman AH; Vendruscolo LF
Neuropharmacology; 2018 Mar; 131():96-103. PubMed ID: 29217282
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional and epigenetic substrates of methamphetamine addiction and withdrawal: evidence from a long-access self-administration model in the rat.
Cadet JL; Brannock C; Jayanthi S; Krasnova IN
Mol Neurobiol; 2015 Apr; 51(2):696-717. PubMed ID: 24939695
[TBL] [Abstract][Full Text] [Related]
15. Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity.
Nakajima A; Yamada K; Nagai T; Uchiyama T; Miyamoto Y; Mamiya T; He J; Nitta A; Mizuno M; Tran MH; Seto A; Yoshimura M; Kitaichi K; Hasegawa T; Saito K; Yamada Y; Seishima M; Sekikawa K; Kim HC; Nabeshima T
J Neurosci; 2004 Mar; 24(9):2212-25. PubMed ID: 14999072
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat.
Krasnova IN; Justinova Z; Ladenheim B; Jayanthi S; McCoy MT; Barnes C; Warner JE; Goldberg SR; Cadet JL
PLoS One; 2010 Jan; 5(1):e8790. PubMed ID: 20098750
[TBL] [Abstract][Full Text] [Related]
17. High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine.
Motbey CP; Clemens KJ; Apetz N; Winstock AR; Ramsey J; Li KM; Wyatt N; Callaghan PD; Bowen MT; Cornish JL; McGregor IS
J Psychopharmacol; 2013 Sep; 27(9):823-36. PubMed ID: 23739178
[TBL] [Abstract][Full Text] [Related]
18. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
Truong JG; Wilkins DG; Baudys J; Crouch DJ; Johnson-Davis KL; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2005 Sep; 314(3):1087-92. PubMed ID: 15901804
[TBL] [Abstract][Full Text] [Related]
19. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Horton DB; Siripurapu KB; Norrholm SD; Culver JP; Hojahmat M; Beckmann JS; Harrod SB; Deaciuc AG; Bardo MT; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Mar; 336(3):940-51. PubMed ID: 21177475
[TBL] [Abstract][Full Text] [Related]
20. Histamine h3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release.
Munzar P; Tanda G; Justinova Z; Goldberg SR
Neuropsychopharmacology; 2004 Apr; 29(4):705-17. PubMed ID: 14735131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
